Skip to main content

Table 12 What QTAP can evaluate in an in vivo study

From: A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood–brain barrier in ddY, FVB, and C57BL/6J mice

1. Inter-organ difference in protein abundance.
2. Differences in functional protein localization in various organs and their impact on pharmacokinetics, efficacy, and drug toxicity.
3. Assay system of ADMET and efficacy based on differences in functional protein abundance in organs.
4. Characteristics of transgenic or gene-knockout animals based on the expression levels of a target protein and other non-target proteins.
5. Consistency between the characteristics of xenograft-transplanted animals and human diseases.
6. Inter-colony, inter-strain, inter-sex, inter-species, inter-racial, inter-disease, and intra-disease differences in the expression levels of functional proteins.
7. Impact of circadian rhythm and developing/aging on functional proteins.
8. Prediction of ADMET and efficacy of drugs in animals and humans, including the diseased state, based on the absolute levels of functional proteins.
9. Determinant factors that can affect inter-individual differences in ADMET, drug efficacy, and their impact on personalized medicine.
10. Suitable choice of molecular target-based drugs based on the absolute levels of target proteins in a drug-targeting organ.
  1. ADMET, absorption, distribution, metabolism, elimination, and toxicity.